Analyst Report: COO

1. EXECUTIVE SUMMARY

Shares of The Cooper Companies, Inc. (NASDAQ: COO) suffered a brutal capitulation over the past week, plummeting -21.30% to hit new 52-week lows in the $53–$54 range. The aggressive selloff was triggered by a disappointing fiscal Q3 2026 earnings print on September 9, which featured a revenue miss, a meaningful cut to full-year guidance, and the revelation of severe US channel destocking in its core CooperVision segment. Compounding the fundamental weakness, the Board of Directors concluded its strategic review by opting not to sell or spin off its CooperSurgical business, abruptly pricing out months of M&A speculation. While near-term visibility remains clouded by inventory corrections and analyst downgrades, a newly authorized $3 billion share repurchase program and aggressive insider buying from multiple directors at the $53–$54 level suggest management views the selloff as overdone.

2. THE CATALYST (CRITICAL)

The violent repricing of COO stock was driven by a multi-pronged negative catalyst that materialized post-market on Wednesday, September 9, 2026, during the release of the company's fiscal Q3 2026 earnings. The subsequent market reaction wiped out over $1.7 billion in market capitalization on September 10 alone.

Specific Trigger Events:

• Revenue Miss & Guidance Cut: While adjusted EPS slightly beat consensus ($1.15 vs. $1.12), revenue of $1.07 billion missed the $1.10 billion Street estimate. Management severely lowered Q4 EPS guidance to $1.05–$1.09 (vs. consensus $1.19) and slashed FY2026 full-year EPS guidance to $4.51–$4.55 (vs. consensus $4.63).
• Destocking Shock: Management revealed unexpected "U.S. channel inventory reductions" within its core CooperVision business, specifically noting that legacy hydrogel lenses were down double-digits. They warned this headwind would persist into Q4, spooking the market regarding true end-consumer demand.
• Scrapped M&A Plans: Concluding a months-long strategic review, the Board elected to retain the CooperSurgical unit (fertility, women's health). The market had priced in a premium based on a potential accretive sale or spin-off.
• Wall Street Downgrades: Between September 10 and 11, at least five major brokerages slashed ratings and price targets. William Blair, Piper Sandler, Baird, and BofA all downgraded the stock to Neutral/Market Perform, with price targets aggressively cut (e.g., Piper Sandler cutting its PT from $86 to $59).

3. COMPANY PROFILE

• Company Name: The Cooper Companies, Inc.
• Core Business: The Cooper Companies is a global medical device manufacturer operating through two primary segments. CooperVision (roughly two-thirds of revenue) is one of the world's top manufacturers of contact lenses, specializing in myopia management and silicone hydrogels. CooperSurgical (roughly one-third of revenue) focuses on women's healthcare, offering medical devices for obstetricians/gynecologists and fertility/in-vitro fertilization (IVF) equipment, as well as the Paragard hormone-free IUD.
• Market Cap: ~$10.7 Billion (post-plunge)
• Sector: Healthcare (Medical Devices & Instruments)
• Key Competitors: Alcon Inc. (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
• Recent Performance Context: COO began September trading comfortably in the mid-$70s. It has since broken completely out of its 52-week consolidation, now trading at 52-week lows, destroying year-to-date gains and dragging YTD performance deep into negative territory (-23% as of mid-September).

4. DEEP DIVE ANALYSIS

Is the move justified? The magnitude of the 21.30% plunge reflects both a fundamental reset and the unwinding of event-driven M&A premiums. An unexpected destocking cycle is highly penalizing in a tightly controlled oligopoly like the contact lens market (dominated by COO, ALC, JNJ, BLCO). When one major player points to overflowing distributor channels, the Street immediately assumes either a loss of market share or a broader macroeconomic slowdown in elective vision spending. Furthermore, taking CooperSurgical off the auction block forced arbitrageurs and event-driven funds to immediately liquidate their positions.

Bull Case vs. Bear Case

• The Bear Case: Visibility is extremely low regarding when the US inventory destocking will bottom out. Gross margin improvements to 66.7% were clouded by inventory write-offs rather than pure operational efficiency. Additionally, if consumer spending is tightening globally, the transition from legacy hydrogels to premium daily silicone hydrogels (COO's growth engine) could stall.
• The Bull Case: The stock is now heavily discounted. COO generates massive cash, posting a record $273 million in free cash flow in Q3. The current valuation puts COO trading at ~11.5x - 12x forward fiscal 2027 earnings—a roughly 25% discount to its peer group and historically cheap compared to its 5-year median P/E of ~44x. Management seems to agree: alongside earnings, they authorized a massive $3 billion share repurchase program (equivalent to ~22.7% of outstanding shares).

Institutional / Insider Signals (Form 4 Filings) Insiders are aggressively buying the dip. SEC Form 4 filings from September 14-15, 2026, reveal significant open-market purchases by corporate directors:

• Director Paul Keel purchased 4,701 shares at $53.18 (~$250,000).
• Director Lawrence Kurzius purchased 10,000 shares at $54.00 (~$540,000).
• Director Walter Rosebrough Jr. purchased 10,000 shares at $54.29 ($540,000).

5. TECHNICAL SNAPSHOT

• Key Support Level: $53.00. The stock has established an immediate floor here following the massive gap down. This zone is currently acting as a lifeline.
• Key Resistance Level: $68.50 - $70.00. Former structural support from accumulated volume before the Q3 earnings gap-down will now serve as a heavy resistance ceiling on any relief rally.
• Volume Analysis: The selloff occurred on exceptionally high capitulation volume as institutional investors fled, wiping out $1.7 billion in market value in 24 hours. The subsequent flatlining near $54 indicates short-term exhaustion of sellers.
• Chart Patterns: The chart displays a severe breakaway gap on the daily timeframe. A massive technical void exists between $55 and $68. Technical oscillators (RSI) are flashing deeply oversold.

6. RISK FACTORS

• Prolonged Channel Destocking: If U.S. distributors continue to bleed inventory without reordering into Q1 2027, top-line stagnation will further erode the forward multiple.
• Class Action Litigation: Several investor rights law firms (Levi & Korsinsky, HBSS, Rosen Law Firm) have opened investigations into whether management provided misleading information regarding inventory channel health in prior quarters.
• Debt & Margins: The company carries substantial debt from previous acquisitions, though a recent $2.3 billion revolving credit facility aids liquidity. Any slip in cash flow generation could limit the actual execution of the authorized $3B buyback.
• Upcoming Catalysts to Watch: Q4 2026 Earnings (Expected early December 2026). Investors will focus exclusively on CooperVision's organic growth metrics and forward commentary on the U.S. distributor channel.

7. ACTIONABLE OUTLOOK

• Short-term (1-2 weeks): Consolidation with Mild Upward Bias. With the RSI deeply oversold, the $53 support level holding firm, and multiple directors stepping in to buy millions of dollars in stock on the open market, the selling pressure is largely exhausted. Expect stabilization between $54 and $58.
• Medium-term (1-3 months): Range-Bound / "Penalty Box." The stock will likely remain in Wall Street's "penalty box" until the company can definitively prove the destocking cycle is over. Upside will be capped near the $65 level (where several downgraded price targets now sit), acting as a heavy resistance zone.
• Long-term thesis: Fundamentally Intact but Re-Rated. The structural oligopoly of the global contact lens market has not changed. At ~12x forward earnings backed by record free cash flow, the valuation risk has been thoroughly derisked. The sheer size of the new $3 billion buyback authorization provides a formidable downside buffer, making this an attractive entry point for value-oriented institutional capital willing to look past a 6-month inventory correction.